Patent US3966965A successfully refreshed from Google Patents.
US3966965A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Oxamic acid derivatives for the prevention of immediate type hypersensitivity reactions
Assignee: Wyeth LLC
•
Filing: 1975-01-20
•
Granted: 1976-06-29
•
Expires: 1995-01-20
Abstract
Abstract Anti-allergic agents of ##EQU1## and heterocyclic oxamic acid derivation present the following formula: IN WHICH A is a member selected from the group consisting of 2-thiazolyl, 2-pyridyl, 2-pyridyl-N-oxide, 6-(lower)alkyl-2-pyridyl, 3-cyano-2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 2-pyrazinyl, α-naphthyl, β-naphthyl, phenyl, 2,6-dichlorophenyl, and substituted phenyl moieties containing from one to three substituents in any of the 2,3,4 and 5 positions of the phenyl ring, independently selected from the group consisting of lower alkyl, lower alkylthio, lower alkylsulfinyl, lower alkoxy, hydroxy(lower)-alkoxy, 2-(lower alkoxy oxalyloxy) ethoxy, benzyloxy, N-mono-and di-lower alkylamino(lower)-alkoxy, halo, sulfamyl, polyhalo(lower)alkyl, carbamyl, N-lower alkylcarbamyl, nitro, mono- and di-lower alkylamino, phenylazo, carboxy, lower alkylcarbonyl, cyano, carb(lower)alkoxy, phenoxy(lower)alkoxy, lower alkoxyoxalamido and lower alkoxyoxalamidophenoxy radicals; B, when taken alone, is a member selected from the group consisting of -OH, lower alkoxy, --NH 2 , --NHOH, cyclohexyloxy and phenoxy; and Y is a member selected from the group consisting of oxygen and when taken with B and the carbon atom to which they are attached, forms the moiety ##EQU2##
Inventors
- 👤 John H. Sellstedt
- 👤 Charles J. Guinosso
- 👤 Albert J. Begany
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 20:24
CPC Classifications
C; C07; C07D; C07D257/00; C07D257/02; C07D257/04; C07C; C07C245/00; C07C245/02; C07C245/06; C07C245/08
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
158 words
A process for preventing the release of pharmacological mediators from an immediate hypersensitivity reaction between reaginic type antibodies and an antigen, thereby preventing the symptoms manifest in bronchial asthma, seasonal pollinosis, allergic rhinitis, urticaria, allergic conjunctivitis, food allergy and anaphylactoid reactions of a sensitized animal, which comprises prophylactically administering, orally or prenterally, to said animal an effective amount of a compound of the formula: ##EQU10## in which A is a member selected from the group consisting of α-naphthyl, β-naphthyl, phenyl, 2,6-dichlorophenyl and substituted phenyl moieties containing from one to three substituents in any of the 2,3,4 and 5 positions of the phenyl ring, independently selected from the group consisting of lower alkyl, lower alkylthio, lower alkylsulfinyl, lower alkoxy, hydroxy(lower)alkoxy, 2-(lower alkoxy oxalyloxy)ethoxy, benzyloxy, N-mono- and di-lower alkylamino(lower)alkoxy, halo, sulfamyl, polyhalo(lower)alkyl, carbamyl, N-lower alkylcarbamyl, nitro, mono- and di- lower alkylamino, carboxy, lower alkylcarbonyl, carb(lower)alkoxy, phenoxy(lower)alkoxy, lower alkoxy oxalamido and lower alkoxyoxalamidophenoxy; and B is lower alkoxy, cyclohexyloxy or phenoxy.
Claim 2
Dependent Claim
158 words
A process for preventing the release of pharmacological mediators from an immediate hypersensitivity reaction between reaginic type antibodies and an antigen, thereby preventing the symptoms manifest in bronchial asthma, seasonal pollinosis, allergic rhinitis, urticaria, allergic conjunctivitis, food allergy and anaphylactoid reactions of a sensitized animal, which comprises prophylactically administering, orally or prenterally, to said animal an effective amount of a compound of the formula: ##EQU10## in which A is a member selected from the group consisting of α-naphthyl, β-naphthyl, phenyl, 2,6-dichlorophenyl and substituted phenyl moieties containing from one to three substituents in any of the 2,3,4 and 5 positions of the phenyl ring, independently selected from the group consisting of lower alkyl, lower alkylthio, lower alkylsulfinyl, lower alkoxy, hydroxy(lower)alkoxy, 2-(lower alkoxy oxalyloxy)ethoxy, benzyloxy, N-mono- and di-lower alkylamino(lower)alkoxy, halo, sulfamyl, polyhalo(lower)alkyl, carbamyl, N-lower alkylcarbamyl, nitro, mono- and di- lower alkylamino, carboxy, lower alkylcarbonyl, carb(lower)alkoxy, phenoxy(lower)alkoxy, lower alkoxy oxalamido and lower alkoxyoxalamidophenoxy; and B is lower alkoxy, cyclohexyloxy or phenoxy.
Claim 3
Dependent Claim
87 words
The process of claim 1 wherein said compound is a compound of the formula: ##EQU11## in which A is a member selected from the group consisting of α -naphthyl, β-naphthyl, phenyl, 2,6-dichlorophenyl and substituted phenyl moieties containing from one to three substituents in any of the 2,3,4 and 5 positions of the phenyl ring, independently selected from the group consisting of lower alkyl, fluoro, lower alkoxy, hydroxy(lower)alkoxy, (lower)-alkylthio, N-mono or di-(lower)alkylamino(lower)alkoxy, carbamyl, carb(lower)alkoxy, trifluoromethyl, nitro, (lower)alkoxy oxalamido, phenoxy(lower)alkoxy and 2-(lower alkoxy oxalyloxy)ethoxy; and B is lower alkoxy.
Claim 4
Dependent Claim
116 words
A process for preventing the release of pharmacological mediators from an immediate hypersensitivity reaction between reaginic type antibodies and an antigen, thereby preventing the symptoms manifest in bronchial asthma, seasonal pollinosis, allergic rhinitis, urticaria, allergic conjunctivities, food allergy and anaphylactoid reactions of a sensitized animal, which comprises prophylactically administering to said animal, orally or parenterally, an effective amount of a compound selected from the group consisting of methyl oxanilate, ethyl oxanilate, isopropyl oxanilate, ethyl 3'-methyloxanilate, ethyl 4'-methoxyoxanilate, ethyl 2'-carbamoyl-3'-methoxy oxanilate, secondary butyl 2'-carbamoyl-3'-methoxy oxanilate, ethyl 4'-nitro-3'-trifluoromethyloxanilate, ethyl 1-naphthyl oxamate, ethyl 2'-carbamoyl-3'-(2-hydroxypropoxy) oxanilate, ethyl 2'-carbamoyl-3', 5'-dimethoxy oxanilate, oxalic acid (2-[2-aminocarbonyl-3-ethoxy carbonylcarbonylaminophenoxy]ethyl)ethyl ester,[2'-carbamoyl-3'-(2-hydroxyethoxy)phenyl]oxamic acid ethyl ester, ethyl 3'-benzyloxy-2'-carbamoyloxanilate, ethyl 4'-dimethylamino oxanilate, ethyl 2'-carbamoyl-3'-dimethylaminooxanilate, ethyl 2'-carbamoyl-3'-methylthiooxanilate and ethyl 2'-carbamoyl-3'-methylsulfinyloxanilate.
Claim 5
Dependent Claim
116 words
A process for preventing the release of pharmacological mediators from an immediate hypersensitivity reaction between reaginic type antibodies and an antigen, thereby preventing the symptoms manifest in bronchial asthma, seasonal pollinosis, allergic rhinitis, urticaria, allergic conjunctivities, food allergy and anaphylactoid reactions of a sensitized animal, which comprises prophylactically administering to said animal, orally or parenterally, an effective amount of a compound selected from the group consisting of methyl oxanilate, ethyl oxanilate, isopropyl oxanilate, ethyl 3'-methyloxanilate, ethyl 4'-methoxyoxanilate, ethyl 2'-carbamoyl-3'-methoxy oxanilate, secondary butyl 2'-carbamoyl-3'-methoxy oxanilate, ethyl 4'-nitro-3'-trifluoromethyloxanilate, ethyl 1-naphthyl oxamate, ethyl 2'-carbamoyl-3'-(2-hydroxypropoxy) oxanilate, ethyl 2'-carbamoyl-3', 5'-dimethoxy oxanilate, oxalic acid (2-[2-aminocarbonyl-3-ethoxy carbonylcarbonylaminophenoxy]ethyl)ethyl ester,[2'-carbamoyl-3'-(2-hydroxyethoxy)phenyl]oxamic acid ethyl ester, ethyl 3'-benzyloxy-2'-carbamoyloxanilate, ethyl 4'-dimethylamino oxanilate, ethyl 2'-carbamoyl-3'-dimethylaminooxanilate, ethyl 2'-carbamoyl-3'-methylthiooxanilate and ethyl 2'-carbamoyl-3'-methylsulfinyloxanilate.
Claim 6
Dependent Claim
13 words
The process of claim 2 wherein said compound is, a lower alkyl 2'-carbamoyl-3'-(lower)alkoxyoxanilate.
Claim 7
Dependent Claim
16 words
The process of claim 4 in which said lower alkyl 2'-carbamoyl-3'-(lower)alkoxy oxanilate is ethyl 2'-carbamoyl-3'-methoxy oxanilate.
Claim 8
Dependent Claim
17 words
The process of claim 4 in which said lower alkyl 2'-carbamoyl-3'-(lower)alkoxy oxanilate is secondary butyl 2'-carbamoyl-3'-methoxy oxanilate.
Claim 9
Dependent Claim
14 words
The process of claim 2 wherein said compound is, a lower alkyl 2'-carbamoyl-3'-hydroxy(lower)alkoxy oxanilate.
Claim 10
Dependent Claim
14 words
The process of claim 7 in which said lower alkyl 2'-carbamoyl-3'-hydroxy(lower)alkoxyoxanilate is ethyl 2'-carbamoyl-3'-(2-hydroxypropoxy)oxanilate.
Claim 11
Dependent Claim
15 words
The process of claim 7 in which said lower alkyl 2'-carbomoyl-3'-hydroxy(lower)alkoxy oxanilate is ethyl 2'-carbamoyl-3'-(2-hydroxyethoxy)oxanilate.
References Cited (Backward Citations)
US3852324A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1979-06-29 | 1979-12-29 | 1980-06-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1983-06-29 | 1983-12-29 | 1984-06-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1987-06-29 | 1987-12-29 | 1988-06-29 | $7700.00 | Window Closed / Lapsed |